Form 4: Regulus Therapeutics CEO Acquires Shares Following Vesting of Performance-Based RSUs

Regulus Therapeutics CEO, Joseph P. Hagan, acquired a total of 280,750 shares of common stock following the vesting of performance-based Restricted Stock Units (RSUs).

Summary

• Joseph P. Hagan, CEO of Regulus Therapeutics, acquired 218,750 shares of common stock at $1.36 per share and 62,000 shares at $1.30 per share on January 9, 2025.
• These acquisitions resulted from the vesting of Restricted Stock Units (RSUs) granted on August 10, 2023, and January 12, 2024.
• The RSUs vested upon achievement of specific performance-based milestones, with 50% vesting immediately and the remaining 50% vesting one year later, contingent on continuous service.

Sentiment

Score: 7

Explanation: The document indicates positive performance as the vesting of RSUs was triggered by meeting performance milestones. The CEO's increased shareholding is also a positive sign. However, it is a routine filing and not a major event.

Positives

• The vesting of performance-based RSUs indicates that the company has met certain performance milestones.
• The CEO's acquisition of shares through vesting aligns his interests with those of the shareholders.

Future Outlook

The remaining 50% of the RSUs will vest one year after the initial vesting date, subject to the reporting person's continuous service to Regulus.

Industry Context

This type of share acquisition through vesting of performance-based RSUs is a common practice in the biotechnology industry to incentivize and align management with company performance and shareholder value.

Comparison to Industry Standards

• The use of performance-based RSUs is a standard practice in the biotech industry, similar to companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals, which also use equity-based compensation to align management with company goals.
• The vesting schedule of 50% immediately upon milestone achievement and 50% after one year is also a common structure, designed to retain key personnel and reward long-term performance.

Stakeholder Impact

• The acquisition of shares by the CEO may be viewed positively by shareholders, as it aligns management's interests with the company's performance.
• The vesting of RSUs indicates that the company has met certain performance milestones, which is beneficial for all stakeholders.

Next Steps

• The remaining 50% of the RSUs granted on August 10, 2023, will vest on the one-year anniversary of the initial vesting date, subject to the reporting person's continuous service.
• The remaining 50% of the RSUs granted on January 12, 2024, will vest on the one-year anniversary of the initial vesting date, subject to the reporting person's continuous service.

Key Dates

Keywords

Regulus Therapeutics, Joseph P. Hagan, Restricted Stock Units, RSUs, Share Acquisition, Performance-Based Vesting, CEO, Stock Options